Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?

M-PEG-TA由甲氧基聚乙二醇和硫辛酸通过化学反应连接而成。Methoxy PEG作为一种亲水性的聚合物链，具有多个反应活性位点，可以与硫辛酸分子进行化学连接。在反应过程中，Methoxy PEG的末端官能团可能与硫辛酸中的特定官能团发生反应，形成稳定的化学键连接。

It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company’s lead program is GH001 ...

Clearmind Medicine (CMND) has signed a non-binding Letter of Intent with Polyrizon (PLRZ) to develop a novel intranasal formulation for its ...

Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatmentsVancouver, Canada, March 19, ...

Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind's psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: ...

Eleusis' drug will slot into Beckley's pipeline alongside lead drug BPL-003, an intranasal formulation of psychoactive compound 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) heading for phase 2 ...

After hours: March 17 at 4:05:02 PM EDT Loading Chart for GHRS ...

After hours: March 14 at 7:35:11 p.m. EDT Loading Chart for GHRS ...